Increasing demand for clinical retinal degeneration therapies featuring human ESC/iPSC-derived retinal tissue and cells warrants proof-of-concept studies. Here, we established two mouse models of end-stage retinal degeneration with immunodeficiency, NOG-rd1-2J and NOG-rd10, and characterized disease progress and immunodeficient status. We also transplanted human ESC-derived retinal sheets into NOG-rd1-2J and confirmed their long-term survival and maturation of the structured graft photoreceptor layer, without rejection or tumorigenesis. We recorded light responses from the host ganglion cells using a multi-electrode array system; this result was consistent with whole-mount immunostaining suggestive of host-graft synapse formation at the responding sites. This study demonstrates an application of our mouse models and provides a proof of concept for the clinical use of human ESC-derived retinal sheets.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918611PMC
http://dx.doi.org/10.1016/j.stemcr.2018.01.032DOI Listing

Publication Analysis

Top Keywords

retinal degeneration
12
human esc-derived
12
esc-derived retinal
12
retinal sheets
12
mouse models
8
retinal
7
establishment immunodeficient
4
immunodeficient retinal
4
degeneration model
4
model mice
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!